McKesson heads into the back half of August with a notable split between what the Street is saying and what options traders are doing — a divergence worth watching closely after a week that saw the stock slip 3.6% to $869.26.
The analyst picture has turned decisively more constructive. Barclays raised its target to $1,000 from $925 today, maintaining Overweight, while RBC Capital initiated fresh coverage at Sector Perform with an $845 target. That follows a string of post-earnings target lifts: UBS bumped to $1,080, Evercore ISI moved to $1,000, and TD Cowen raised to $1,006 — all within the past two weeks. The consensus sits at Hold with a mean target near $987, implying roughly 13.5% upside from current levels. Bulls point to McKesson's dominant position in pharmaceutical distribution and its oncology channel exposure. Bears — RBC among them with its below-consensus $845 target — are more cautious on near-term margin expansion given generic pricing pressure and the looming threat from healthcare supply chain disruptors.
Options positioning tells a more defensive story, and it has not resolved the way yesterday's note flagged it might. The put/call ratio eased fractionally to 0.609 from 0.617 on Monday, but remains nearly two standard deviations above its 20-day mean of 0.537. That is the second-highest defensive reading of the past year. The PCR was running near 0.501 at the start of August, just before earnings. The post-earnings relief rally was brief; hedging demand crept back almost immediately and has been sticky since.
Short interest has eased slightly — down about 1.2% in the latest session to 2.93% of free float — but the weekly picture still shows an 8% build from the August 10 trough. That is consistent with shorts rebuilding positions after covering into the earnings beat. Crucially, the borrow market continues to send a contradictory signal: availability is exceptionally loose at over 8,400% of short interest, and cost to borrow has dropped sharply, now running at just 0.30% annually — less than half its level from earlier in the month. With shares so easily and cheaply sourced, the short rebuild looks opportunistic rather than conviction-driven. There is no squeeze pressure in the lending market whatsoever.
Institutional ownership is broadly stable. JP Morgan Asset Management added 425,501 shares through July, a notable accumulation. Arrowstreet built 239,786 shares in the quarter through June. BlackRock and State Street each added modestly. On the insider side, the pattern has been one-directional: CEO Brian Tyler sold shares three times between early June and early July, totalling roughly $17 million in proceeds, at prices ranging from $763 to $794 — well below today's $869 level. That sequence preceded a meaningful re-rating, though the sales themselves were disclosed at low-significance levels and are consistent with planned disposal programs.
The next scheduled earnings event is November 4. What to watch between now and then is whether the put/call ratio, which has been elevated and sticky since mid-August, begins to unwind as the share price stabilises — or whether the options caution deepens further on any deterioration in the healthcare policy backdrop, particularly around Medicaid reimbursement rates and specialty drug channel dynamics.
See the live data behind this article on ORTEX.
Open MCK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
